Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-26 @ 12:14 PM
Ignite Modification Date:
2025-12-26 @ 12:14 PM
NCT ID:
NCT03914300
Group ID:
EG000
Title:
Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab)
Description:
Patients receive cabozantinib S-malate PO QD on days -14 to -1 prior to cycle 1, days 1-42 of cycles 1-4 and days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1, 15, and 29 of cycles 1-4 and day 1 of subsequent cycles and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Treatment repeats every 42 days for cycles 1-4 and every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening, and blood sample collection throughout the study.
Biospecimen Collection: Undergo blood sample collection
Cabozantinib S-malate: Given PO
Computed Tomography: Undergo CT
Ipilimumab: Given IV
Magnetic Resonance Imaging: Undergo MRI
Nivolumab: Given IV
Deaths Number Affected:
7
Deaths Number At Risk:
None
Serious Number Affected:
6
Serious Number At Risk:
11
Other Number Affected:
11
Other Number At Risk:
11
Study:
NCT03914300
Results Section:
NCT03914300
Adverse Events Module:
NCT03914300